Skip to content

Real Time Continuous Glucose Monitoring in Neonatal Intensive Care

Real Time Continuous Glucose Monitoring in Neonatal Intensive Care - REACT study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47310
Enrollment
40
Registered
2019-01-15
Start date
2017-07-26
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypo- and hyperglycaemia in premature children

Interventions

Glucose
premature

Sponsors

Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: * Informed consent of the parents * * 33+6 weeks gestation * * 24 hours of age * Birth weight * 1200 g

Exclusion criteria

Exclusion criteria: * A fatal congenital defect known at the time of enrolment in the study. * All congenital metabolic disorders known at the time of enrolment in the study. * Newborns who in the opinion of the treating doctor have no realistic prospect of survival at the time of enrolment in the study

Design outcomes

Primary

MeasureTime frame
Time percentage of sensor glucose (SG) within the target of 2.6-10 mmol/L within the first six days of life of premature children

Secondary

MeasureTime frame
Efficacy 1) Mean sensor glucose (SG) in the first six days. 2) Time percentage of SG within the target of 4-8 mmol/L within the first six days of life 3) SG variability in individuals as established by standard deviation in the patient 4) Time percentage of glucose levels in hyperglycaemic region - SG > 15 mmol/L Acceptability 1) Assessment score of the clinical staff on the impact on clinical care 2) Frequency of blood glucose monitoring 3) Clinical use of algorithm Safety 1) Incidence of hypoglycaemia defined as an episode of blood glucose >2.2 mmol/L and 1 hour 3) Incidence of severe hypoglycaemia defined as an episode of BG *2.2 mmol/L Economic aspects for health care * Cost efficiency expressed in terms of increasing costs per additional case of adequate glucose control between 2.6 mmol/L - 10 mmol/L

Countries

Netherlands, Spain, United Kingdom

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)